CA1111765A - Reductant composition for technetium-99m and method for making technetium-99m labelled ligands - Google Patents
Reductant composition for technetium-99m and method for making technetium-99m labelled ligandsInfo
- Publication number
- CA1111765A CA1111765A CA319,663A CA319663A CA1111765A CA 1111765 A CA1111765 A CA 1111765A CA 319663 A CA319663 A CA 319663A CA 1111765 A CA1111765 A CA 1111765A
- Authority
- CA
- Canada
- Prior art keywords
- ligand
- substrate
- technetium
- labelled
- product
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired
Links
- 239000003446 ligand Substances 0.000 title claims abstract description 152
- 239000003638 chemical reducing agent Substances 0.000 title claims abstract description 111
- 239000000203 mixture Substances 0.000 title claims abstract description 14
- GKLVYJBZJHMRIY-OUBTZVSYSA-N Technetium-99 Chemical compound [99Tc] GKLVYJBZJHMRIY-OUBTZVSYSA-N 0.000 title claims description 31
- 229940056501 technetium 99m Drugs 0.000 title claims description 31
- 238000000034 method Methods 0.000 title claims description 29
- 239000000758 substrate Substances 0.000 claims abstract description 62
- GKLVYJBZJHMRIY-UHFFFAOYSA-N technetium atom Chemical compound [Tc] GKLVYJBZJHMRIY-UHFFFAOYSA-N 0.000 claims abstract description 42
- 229910052713 technetium Inorganic materials 0.000 claims abstract description 36
- 230000003647 oxidation Effects 0.000 claims abstract description 18
- 238000007254 oxidation reaction Methods 0.000 claims abstract description 18
- 238000002156 mixing Methods 0.000 claims abstract description 9
- 150000002500 ions Chemical class 0.000 claims description 23
- 239000012217 radiopharmaceutical Substances 0.000 claims description 20
- 239000011521 glass Substances 0.000 claims description 19
- 229940121896 radiopharmaceutical Drugs 0.000 claims description 18
- 230000002799 radiopharmaceutical effect Effects 0.000 claims description 17
- 150000001875 compounds Chemical class 0.000 claims description 15
- NBZBKCUXIYYUSX-UHFFFAOYSA-N iminodiacetic acid Chemical compound OC(=O)CNCC(O)=O NBZBKCUXIYYUSX-UHFFFAOYSA-N 0.000 claims description 12
- 239000000463 material Substances 0.000 claims description 12
- 239000011324 bead Substances 0.000 claims description 11
- 229920005615 natural polymer Polymers 0.000 claims description 11
- 229920001059 synthetic polymer Polymers 0.000 claims description 11
- 239000005725 8-Hydroxyquinoline Substances 0.000 claims description 8
- 229960003540 oxyquinoline Drugs 0.000 claims description 8
- MCJGNVYPOGVAJF-UHFFFAOYSA-N quinolin-8-ol Chemical compound C1=CN=C2C(O)=CC=CC2=C1 MCJGNVYPOGVAJF-UHFFFAOYSA-N 0.000 claims description 8
- CWYNVVGOOAEACU-UHFFFAOYSA-N Fe2+ Chemical compound [Fe+2] CWYNVVGOOAEACU-UHFFFAOYSA-N 0.000 claims description 7
- 239000002253 acid Substances 0.000 claims description 7
- VLYUGYAKYZETRF-UHFFFAOYSA-N dihydrolipoamide Chemical compound NC(=O)CCCCC(S)CCS VLYUGYAKYZETRF-UHFFFAOYSA-N 0.000 claims description 7
- QCWXUUIWCKQGHC-UHFFFAOYSA-N Zirconium Chemical compound [Zr] QCWXUUIWCKQGHC-UHFFFAOYSA-N 0.000 claims description 6
- -1 dihydro-lipoamine Chemical compound 0.000 claims description 6
- 125000000524 functional group Chemical group 0.000 claims description 6
- 229910052726 zirconium Inorganic materials 0.000 claims description 6
- 229910019142 PO4 Inorganic materials 0.000 claims description 5
- FATUQANACHZLRT-KMRXSBRUSA-L calcium glucoheptonate Chemical compound [Ca+2].OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C(O)C([O-])=O.OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C(O)C([O-])=O FATUQANACHZLRT-KMRXSBRUSA-L 0.000 claims description 5
- 235000021317 phosphate Nutrition 0.000 claims description 5
- 102000009027 Albumins Human genes 0.000 claims description 4
- 108010088751 Albumins Proteins 0.000 claims description 4
- 102000004506 Blood Proteins Human genes 0.000 claims description 4
- 108010017384 Blood Proteins Proteins 0.000 claims description 4
- RGHNJXZEOKUKBD-SQOUGZDYSA-M D-gluconate Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O RGHNJXZEOKUKBD-SQOUGZDYSA-M 0.000 claims description 4
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 claims description 4
- IMQLKJBTEOYOSI-GPIVLXJGSA-N Inositol-hexakisphosphate Chemical compound OP(O)(=O)O[C@H]1[C@H](OP(O)(O)=O)[C@@H](OP(O)(O)=O)[C@H](OP(O)(O)=O)[C@H](OP(O)(O)=O)[C@@H]1OP(O)(O)=O IMQLKJBTEOYOSI-GPIVLXJGSA-N 0.000 claims description 4
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims description 4
- 229940050410 gluconate Drugs 0.000 claims description 4
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 4
- MBKDYNNUVRNNRF-UHFFFAOYSA-N medronic acid Chemical compound OP(O)(=O)CP(O)(O)=O MBKDYNNUVRNNRF-UHFFFAOYSA-N 0.000 claims description 4
- 229940102859 methylene diphosphonate Drugs 0.000 claims description 4
- 239000002245 particle Substances 0.000 claims description 4
- 235000002949 phytic acid Nutrition 0.000 claims description 4
- XPPKVPWEQAFLFU-UHFFFAOYSA-J diphosphate(4-) Chemical compound [O-]P([O-])(=O)OP([O-])([O-])=O XPPKVPWEQAFLFU-UHFFFAOYSA-J 0.000 claims description 3
- 235000011180 diphosphates Nutrition 0.000 claims description 3
- 239000010452 phosphate Substances 0.000 claims description 3
- ABLZXFCXXLZCGV-UHFFFAOYSA-N Phosphorous acid Chemical class OP(O)=O ABLZXFCXXLZCGV-UHFFFAOYSA-N 0.000 claims description 2
- 150000007513 acids Chemical class 0.000 claims description 2
- XOHQAXXZXMHLPT-UHFFFAOYSA-N ethyl(phosphonooxy)phosphinic acid Chemical compound CCP(O)(=O)OP(O)(O)=O XOHQAXXZXMHLPT-UHFFFAOYSA-N 0.000 claims description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 claims description 2
- 150000003013 phosphoric acid derivatives Chemical class 0.000 claims description 2
- OUDSFQBUEBFSPS-UHFFFAOYSA-N ethylenediaminetriacetic acid Chemical compound OC(=O)CNCCN(CC(O)=O)CC(O)=O OUDSFQBUEBFSPS-UHFFFAOYSA-N 0.000 claims 7
- 125000005842 heteroatom Chemical group 0.000 claims 5
- 229910001448 ferrous ion Inorganic materials 0.000 claims 4
- 125000004585 polycyclic heterocycle group Chemical group 0.000 claims 4
- 102000008946 Fibrinogen Human genes 0.000 claims 3
- 108010049003 Fibrinogen Proteins 0.000 claims 3
- 229940012952 fibrinogen Drugs 0.000 claims 3
- 108010074605 gamma-Globulins Proteins 0.000 claims 3
- XFQYOFLFNKCHLG-UHFFFAOYSA-N 3-acetyl-6-bromochromen-2-one Chemical compound BrC1=CC=C2OC(=O)C(C(=O)C)=CC2=C1 XFQYOFLFNKCHLG-UHFFFAOYSA-N 0.000 claims 2
- QPCDCPDFJACHGM-UHFFFAOYSA-N N,N-bis{2-[bis(carboxymethyl)amino]ethyl}glycine Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(=O)O)CCN(CC(O)=O)CC(O)=O QPCDCPDFJACHGM-UHFFFAOYSA-N 0.000 claims 2
- 229960001484 edetic acid Drugs 0.000 claims 2
- 229960003330 pentetic acid Drugs 0.000 claims 2
- KXDHJXZQYSOELW-UHFFFAOYSA-N Carbamic acid Chemical class NC(O)=O KXDHJXZQYSOELW-UHFFFAOYSA-N 0.000 claims 1
- RWSOTUBLDIXVET-UHFFFAOYSA-N Dihydrogen sulfide Chemical class S RWSOTUBLDIXVET-UHFFFAOYSA-N 0.000 claims 1
- 125000003289 ascorbyl group Chemical class [H]O[C@@]([H])(C([H])([H])O*)[C@@]1([H])OC(=O)C(O*)=C1O* 0.000 claims 1
- XQRLCLUYWUNEEH-UHFFFAOYSA-L diphosphonate(2-) Chemical compound [O-]P(=O)OP([O-])=O XQRLCLUYWUNEEH-UHFFFAOYSA-L 0.000 claims 1
- 229940048084 pyrophosphate Drugs 0.000 claims 1
- 238000002360 preparation method Methods 0.000 abstract description 3
- ZWEHNKRNPOVVGH-UHFFFAOYSA-N 2-Butanone Chemical compound CCC(C)=O ZWEHNKRNPOVVGH-UHFFFAOYSA-N 0.000 description 39
- 239000000047 product Substances 0.000 description 23
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 22
- 239000000243 solution Substances 0.000 description 17
- 239000011780 sodium chloride Substances 0.000 description 13
- 239000003795 chemical substances by application Substances 0.000 description 12
- 102000008100 Human Serum Albumin Human genes 0.000 description 10
- 108091006905 Human Serum Albumin Proteins 0.000 description 10
- 210000004369 blood Anatomy 0.000 description 9
- 239000008280 blood Substances 0.000 description 9
- 238000004587 chromatography analysis Methods 0.000 description 7
- 238000002372 labelling Methods 0.000 description 7
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 6
- 206010061216 Infarction Diseases 0.000 description 6
- 241000699670 Mus sp. Species 0.000 description 6
- 241000700159 Rattus Species 0.000 description 6
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 6
- 230000007574 infarction Effects 0.000 description 6
- 229910052718 tin Inorganic materials 0.000 description 6
- 210000003462 vein Anatomy 0.000 description 6
- 230000037396 body weight Effects 0.000 description 5
- 238000011156 evaluation Methods 0.000 description 5
- 210000003734 kidney Anatomy 0.000 description 5
- 229910021645 metal ion Inorganic materials 0.000 description 5
- 210000000056 organ Anatomy 0.000 description 5
- 210000002784 stomach Anatomy 0.000 description 5
- ATJFFYVFTNAWJD-UHFFFAOYSA-N Tin Chemical compound [Sn] ATJFFYVFTNAWJD-UHFFFAOYSA-N 0.000 description 4
- 108010088172 chelatin Proteins 0.000 description 4
- 238000006243 chemical reaction Methods 0.000 description 4
- 239000012216 imaging agent Substances 0.000 description 4
- 238000002347 injection Methods 0.000 description 4
- 239000007924 injection Substances 0.000 description 4
- 210000004185 liver Anatomy 0.000 description 4
- 238000009206 nuclear medicine Methods 0.000 description 4
- 239000011148 porous material Substances 0.000 description 4
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 3
- 229910008066 SnC12 Inorganic materials 0.000 description 3
- 210000000988 bone and bone Anatomy 0.000 description 3
- 229920001429 chelating resin Polymers 0.000 description 3
- 239000007789 gas Substances 0.000 description 3
- 150000004676 glycans Chemical class 0.000 description 3
- DJQJFMSHHYAZJD-UHFFFAOYSA-N lidofenin Chemical compound CC1=CC=CC(C)=C1NC(=O)CN(CC(O)=O)CC(O)=O DJQJFMSHHYAZJD-UHFFFAOYSA-N 0.000 description 3
- 229920000642 polymer Polymers 0.000 description 3
- 229920001282 polysaccharide Polymers 0.000 description 3
- 239000005017 polysaccharide Substances 0.000 description 3
- 230000002285 radioactive effect Effects 0.000 description 3
- 210000001519 tissue Anatomy 0.000 description 3
- TXUICONDJPYNPY-UHFFFAOYSA-N (1,10,13-trimethyl-3-oxo-4,5,6,7,8,9,11,12,14,15,16,17-dodecahydrocyclopenta[a]phenanthren-17-yl) heptanoate Chemical compound C1CC2CC(=O)C=C(C)C2(C)C2C1C1CCC(OC(=O)CCCCCC)C1(C)CC2 TXUICONDJPYNPY-UHFFFAOYSA-N 0.000 description 2
- QGJDXUIYIUGQGO-UHFFFAOYSA-N 1-[2-[(2-methylpropan-2-yl)oxycarbonylamino]propanoyl]pyrrolidine-2-carboxylic acid Chemical compound CC(C)(C)OC(=O)NC(C)C(=O)N1CCCC1C(O)=O QGJDXUIYIUGQGO-UHFFFAOYSA-N 0.000 description 2
- NLZUEZXRPGMBCV-UHFFFAOYSA-N Butylhydroxytoluene Chemical group CC1=CC(C(C)(C)C)=C(O)C(C(C)(C)C)=C1 NLZUEZXRPGMBCV-UHFFFAOYSA-N 0.000 description 2
- 241000040710 Chela Species 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 2
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 2
- ZOKXTWBITQBERF-AKLPVKDBSA-N Molybdenum Mo-99 Chemical compound [99Mo] ZOKXTWBITQBERF-AKLPVKDBSA-N 0.000 description 2
- 239000004698 Polyethylene Substances 0.000 description 2
- 229910021626 Tin(II) chloride Inorganic materials 0.000 description 2
- 239000008351 acetate buffer Substances 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 125000004429 atom Chemical group 0.000 description 2
- 239000005289 controlled pore glass Substances 0.000 description 2
- 229910001873 dinitrogen Inorganic materials 0.000 description 2
- 229920001971 elastomer Polymers 0.000 description 2
- 238000010828 elution Methods 0.000 description 2
- XLYOFNOQVPJJNP-ZSJDYOACSA-N heavy water Substances [2H]O[2H] XLYOFNOQVPJJNP-ZSJDYOACSA-N 0.000 description 2
- 238000003384 imaging method Methods 0.000 description 2
- 210000004072 lung Anatomy 0.000 description 2
- 229910052751 metal Inorganic materials 0.000 description 2
- 239000002184 metal Substances 0.000 description 2
- 229950009740 molybdenum mo-99 Drugs 0.000 description 2
- 210000004165 myocardium Anatomy 0.000 description 2
- 229910052757 nitrogen Inorganic materials 0.000 description 2
- JMANVNJQNLATNU-UHFFFAOYSA-N oxalonitrile Chemical compound N#CC#N JMANVNJQNLATNU-UHFFFAOYSA-N 0.000 description 2
- 229920000573 polyethylene Polymers 0.000 description 2
- 239000002244 precipitate Substances 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- 229920005989 resin Polymers 0.000 description 2
- 239000011347 resin Substances 0.000 description 2
- 150000003839 salts Chemical class 0.000 description 2
- 229920006395 saturated elastomer Polymers 0.000 description 2
- 229910052708 sodium Inorganic materials 0.000 description 2
- 239000011734 sodium Substances 0.000 description 2
- 238000001179 sorption measurement Methods 0.000 description 2
- 239000001119 stannous chloride Substances 0.000 description 2
- 235000011150 stannous chloride Nutrition 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- IUTCEZPPWBHGIX-UHFFFAOYSA-N tin(2+) Chemical compound [Sn+2] IUTCEZPPWBHGIX-UHFFFAOYSA-N 0.000 description 2
- 210000000689 upper leg Anatomy 0.000 description 2
- MDAXKAUIABOHTD-UHFFFAOYSA-N 1,4,8,11-tetraazacyclotetradecane Chemical compound C1CNCCNCCCNCCNC1 MDAXKAUIABOHTD-UHFFFAOYSA-N 0.000 description 1
- 241000428352 Amma Species 0.000 description 1
- KUVIULQEHSCUHY-XYWKZLDCSA-N Beclometasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(Cl)[C@@H]1[C@@H]1C[C@H](C)[C@@](C(=O)COC(=O)CC)(OC(=O)CC)[C@@]1(C)C[C@@H]2O KUVIULQEHSCUHY-XYWKZLDCSA-N 0.000 description 1
- 241000861718 Chloris <Aves> Species 0.000 description 1
- 229920000742 Cotton Polymers 0.000 description 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
- 101100536354 Drosophila melanogaster tant gene Proteins 0.000 description 1
- 102100023275 Dual specificity mitogen-activated protein kinase kinase 3 Human genes 0.000 description 1
- 208000005189 Embolism Diseases 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- DBVJJBKOTRCVKF-UHFFFAOYSA-N Etidronic acid Chemical compound OP(=O)(O)C(O)(C)P(O)(O)=O DBVJJBKOTRCVKF-UHFFFAOYSA-N 0.000 description 1
- 102000006395 Globulins Human genes 0.000 description 1
- 108010044091 Globulins Proteins 0.000 description 1
- 101001115394 Homo sapiens Dual specificity mitogen-activated protein kinase kinase 3 Proteins 0.000 description 1
- 241000471154 Lithodesmium variabile Species 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 229920005654 Sephadex Polymers 0.000 description 1
- 239000012507 Sephadex™ Substances 0.000 description 1
- 229920002684 Sepharose Polymers 0.000 description 1
- DPDMMXDBJGCCQC-UHFFFAOYSA-N [Na].[Cl] Chemical compound [Na].[Cl] DPDMMXDBJGCCQC-UHFFFAOYSA-N 0.000 description 1
- VYTBPJNGNGMRFH-UHFFFAOYSA-N acetic acid;azane Chemical compound N.N.CC(O)=O.CC(O)=O.CC(O)=O.CC(O)=O VYTBPJNGNGMRFH-UHFFFAOYSA-N 0.000 description 1
- SLSLCLVPVDMEHA-UHFFFAOYSA-N acetic acid;ethane-1,2-diamine Chemical group CC(O)=O.CC(O)=O.CC(O)=O.NCCN SLSLCLVPVDMEHA-UHFFFAOYSA-N 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 239000011149 active material Substances 0.000 description 1
- PNEYBMLMFCGWSK-UHFFFAOYSA-N aluminium oxide Inorganic materials [O-2].[O-2].[O-2].[Al+3].[Al+3] PNEYBMLMFCGWSK-UHFFFAOYSA-N 0.000 description 1
- 239000012491 analyte Substances 0.000 description 1
- 239000012736 aqueous medium Substances 0.000 description 1
- 208000011775 arteriosclerosis disease Diseases 0.000 description 1
- 229940072107 ascorbate Drugs 0.000 description 1
- 239000011668 ascorbic acid Substances 0.000 description 1
- 239000012298 atmosphere Substances 0.000 description 1
- 125000002619 bicyclic group Chemical group 0.000 description 1
- 230000036770 blood supply Effects 0.000 description 1
- 210000001185 bone marrow Anatomy 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 150000001732 carboxylic acid derivatives Chemical class 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 238000012512 characterization method Methods 0.000 description 1
- 239000002738 chelating agent Substances 0.000 description 1
- 238000012412 chemical coupling Methods 0.000 description 1
- BJFGVYCULWBXKF-UHFFFAOYSA-M chlormerodrin Chemical compound Cl[Hg]CC(OC)CNC(N)=O BJFGVYCULWBXKF-UHFFFAOYSA-M 0.000 description 1
- 229950002901 chlormerodrin Drugs 0.000 description 1
- 239000000084 colloidal system Substances 0.000 description 1
- 230000000536 complexating effect Effects 0.000 description 1
- 230000001276 controlling effect Effects 0.000 description 1
- 150000004038 corrins Chemical class 0.000 description 1
- ATDGTVJJHBUTRL-UHFFFAOYSA-N cyanogen bromide Chemical compound BrC#N ATDGTVJJHBUTRL-UHFFFAOYSA-N 0.000 description 1
- 125000004122 cyclic group Chemical group 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 238000002405 diagnostic procedure Methods 0.000 description 1
- MCWXGJITAZMZEV-UHFFFAOYSA-N dimethoate Chemical compound CNC(=O)CSP(=S)(OC)OC MCWXGJITAZMZEV-UHFFFAOYSA-N 0.000 description 1
- SDIXRDNYIMOKSG-UHFFFAOYSA-L disodium methyl arsenate Chemical compound [Na+].[Na+].C[As]([O-])([O-])=O SDIXRDNYIMOKSG-UHFFFAOYSA-L 0.000 description 1
- MYRTYDVEIRVNKP-UHFFFAOYSA-N divinylbenzene Substances C=CC1=CC=CC=C1C=C MYRTYDVEIRVNKP-UHFFFAOYSA-N 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 230000002526 effect on cardiovascular system Effects 0.000 description 1
- 210000003743 erythrocyte Anatomy 0.000 description 1
- 239000012467 final product Substances 0.000 description 1
- GNBHRKFJIUUOQI-UHFFFAOYSA-N fluorescein Chemical compound O1C(=O)C2=CC=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 GNBHRKFJIUUOQI-UHFFFAOYSA-N 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 238000002523 gelfiltration Methods 0.000 description 1
- 150000004820 halides Chemical class 0.000 description 1
- ATADHKWKHYVBTJ-UHFFFAOYSA-N hydron;4-[1-hydroxy-2-(methylamino)ethyl]benzene-1,2-diol;chloride Chemical compound Cl.CNCC(O)C1=CC=C(O)C(O)=C1 ATADHKWKHYVBTJ-UHFFFAOYSA-N 0.000 description 1
- 238000010253 intravenous injection Methods 0.000 description 1
- 238000005342 ion exchange Methods 0.000 description 1
- 125000005647 linker group Chemical group 0.000 description 1
- 230000003908 liver function Effects 0.000 description 1
- 238000011068 loading method Methods 0.000 description 1
- 150000002678 macrocyclic compounds Chemical class 0.000 description 1
- 150000002730 mercury Chemical class 0.000 description 1
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 230000033116 oxidation-reduction process Effects 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 229940127557 pharmaceutical product Drugs 0.000 description 1
- JTJMJGYZQZDUJJ-UHFFFAOYSA-N phencyclidine Chemical compound C1CCCCN1C1(C=2C=CC=CC=2)CCCCC1 JTJMJGYZQZDUJJ-UHFFFAOYSA-N 0.000 description 1
- UEZVMMHDMIWARA-UHFFFAOYSA-M phosphonate Chemical compound [O-]P(=O)=O UEZVMMHDMIWARA-UHFFFAOYSA-M 0.000 description 1
- 125000003367 polycyclic group Chemical group 0.000 description 1
- WSHYKIAQCMIPTB-UHFFFAOYSA-M potassium;2-oxo-3-(3-oxo-1-phenylbutyl)chromen-4-olate Chemical compound [K+].[O-]C=1C2=CC=CC=C2OC(=O)C=1C(CC(=O)C)C1=CC=CC=C1 WSHYKIAQCMIPTB-UHFFFAOYSA-M 0.000 description 1
- 238000004094 preconcentration Methods 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 230000005855 radiation Effects 0.000 description 1
- 239000000700 radioactive tracer Substances 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- IOVGROKTTNBUGK-SJCJKPOMSA-N ritodrine Chemical compound N([C@@H](C)[C@H](O)C=1C=CC(O)=CC=1)CCC1=CC=C(O)C=C1 IOVGROKTTNBUGK-SJCJKPOMSA-N 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- BHZOKUMUHVTPBX-UHFFFAOYSA-M sodium acetic acid acetate Chemical compound [Na+].CC(O)=O.CC([O-])=O BHZOKUMUHVTPBX-UHFFFAOYSA-M 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 101150008563 spir gene Proteins 0.000 description 1
- 210000000952 spleen Anatomy 0.000 description 1
- 229940007163 stannous tartrate Drugs 0.000 description 1
- ACTRVOBWPAIOHC-UHFFFAOYSA-N succimer Chemical compound OC(=O)C(S)C(S)C(O)=O ACTRVOBWPAIOHC-UHFFFAOYSA-N 0.000 description 1
- 125000004434 sulfur atom Chemical group 0.000 description 1
- 235000013619 trace mineral Nutrition 0.000 description 1
- 239000011573 trace mineral Substances 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C01—INORGANIC CHEMISTRY
- C01G—COMPOUNDS CONTAINING METALS NOT COVERED BY SUBCLASSES C01D OR C01F
- C01G99/00—Subject matter not provided for in other groups of this subclass
- C01G99/006—Compounds containing a metal not provided for elsewhere in this subclass, with or without oxygen or hydrogen, and containing two or more other elements
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/0474—Organic compounds complexes or complex-forming compounds, i.e. wherein a radioactive metal (e.g. 111In3+) is complexed or chelated by, e.g. a N2S2, N3S, NS3, N4 chelating group
- A61K51/0478—Organic compounds complexes or complex-forming compounds, i.e. wherein a radioactive metal (e.g. 111In3+) is complexed or chelated by, e.g. a N2S2, N3S, NS3, N4 chelating group complexes from non-cyclic ligands, e.g. EDTA, MAG3
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/12—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by a special physical form, e.g. emulsion, microcapsules, liposomes, characterized by a special physical form, e.g. emulsions, dispersions, microcapsules
- A61K51/1282—Devices used in vivo and carrying the radioactive therapeutic or diagnostic agent, therapeutic or in vivo diagnostic kits, stents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2123/00—Preparations for testing in vivo
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Physics & Mathematics (AREA)
- Optics & Photonics (AREA)
- Life Sciences & Earth Sciences (AREA)
- Epidemiology (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Organic Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Inorganic Chemistry (AREA)
- Heart & Thoracic Surgery (AREA)
- Dispersion Chemistry (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US05/909,385 US4272503A (en) | 1978-05-25 | 1978-05-25 | Reductant composition for technetium-99m and method for making technetium-99m labelled ligands |
| US909,385 | 1978-05-25 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA1111765A true CA1111765A (en) | 1981-11-03 |
Family
ID=25427158
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA319,663A Expired CA1111765A (en) | 1978-05-25 | 1979-01-15 | Reductant composition for technetium-99m and method for making technetium-99m labelled ligands |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US4272503A (cg-RX-API-DMAC7.html) |
| JP (2) | JPS54160305A (cg-RX-API-DMAC7.html) |
| BE (1) | BE876562A (cg-RX-API-DMAC7.html) |
| CA (1) | CA1111765A (cg-RX-API-DMAC7.html) |
| CH (1) | CH649924A5 (cg-RX-API-DMAC7.html) |
| DE (1) | DE2920770A1 (cg-RX-API-DMAC7.html) |
| FR (1) | FR2430236A1 (cg-RX-API-DMAC7.html) |
| GB (1) | GB2023327B (cg-RX-API-DMAC7.html) |
| NL (1) | NL7904059A (cg-RX-API-DMAC7.html) |
| SE (1) | SE7904316L (cg-RX-API-DMAC7.html) |
Families Citing this family (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4421735A (en) * | 1980-04-17 | 1983-12-20 | The Massachusetts General Hospital | Radiolabeled diagnostic compositions and method for making the same |
| US4406876A (en) * | 1980-10-14 | 1983-09-27 | Research Foundation Of The State Univ. Of New York | Sulfur free small-particle production of technetium sulfur colloid |
| US4436718A (en) | 1981-10-13 | 1984-03-13 | Pierce Chemical Company | Iodinating reagent |
| ES8404857A1 (es) * | 1981-10-27 | 1984-05-16 | Hybritech Inc | Un procedimiento para preparar un anticuerpo monoclonal para un antigeno asociado a un tumor. |
| DE3237573A1 (de) * | 1982-10-09 | 1984-04-12 | Hoechst Ag, 6230 Frankfurt | Technetium-99m-tri- und tetraphosphonate zur szintigraphischen dastellung res-haltiger organe und der lymphgefaesse und verfahren zu deren herstellung |
| US4574079A (en) * | 1983-05-27 | 1986-03-04 | Gavras Haralambos P | Radiolabeled angiotensin converting enzyme inhibitors for radiolabeling mammalian organ sites |
| EP0163701A1 (en) * | 1983-12-06 | 1985-12-11 | The Royal Melbourne Hospital | PREPARATION OF RADIOPHARMACEUTICALS BASED ON TECHNETIUM-99m/ |
| USRE38435E1 (en) * | 1983-12-28 | 2004-02-24 | Daicel Chemical Industries, Ltd. | Separating agent |
| US4707352A (en) * | 1984-01-30 | 1987-11-17 | Enzo Biochem, Inc. | Method of radioactively labeling diagnostic and therapeutic agents containing a chelating group |
| US5164175A (en) * | 1986-12-10 | 1992-11-17 | Hoechst Aktiengesellschaft | Diagnostic aid containing an organ-specific substance labeled with technetium-99m |
| US5059541A (en) * | 1988-04-29 | 1991-10-22 | Neorx Corporation | Minimal derivatization of proteins |
| US5208007A (en) * | 1988-11-22 | 1993-05-04 | Board Of Regents Of The University Of Oklahoma | Isotopic tracer composition and method for making and using same |
| US5808091A (en) * | 1991-10-29 | 1998-09-15 | Bracco International B.V. | Rhenium and technetium complexes containing a hypoxia localizing moiety |
| MXPA94002323A (es) * | 1993-03-31 | 2002-06-18 | Mallinckrodt Medical Inc | Formulaciones radiofarmaceuticas que tienen reductores no estanosos. |
| US5608110A (en) * | 1993-06-15 | 1997-03-04 | Bracco International B.V. | Heteroatom-bearing ligands and metal complexes thereof |
| ATE334704T1 (de) * | 1993-11-16 | 2006-08-15 | Bracco Int Bv | Immobilisiertes markierungsverfahren |
| US5774782A (en) * | 1996-05-22 | 1998-06-30 | Lockheed Martin Energy Systems, Inc. | Technetium-99m generator system |
| WO2002082051A2 (en) * | 2001-01-17 | 2002-10-17 | Tubbs Kemmons A | An integrated high throughput system for the analysis of biomolecules |
| US7799526B2 (en) * | 2002-11-21 | 2010-09-21 | The University Of North Carolina At Chapel Hill | Phosphoprotein detection reagent and methods of making and using the same |
| GB0804406D0 (en) * | 2008-03-10 | 2008-04-16 | Univ Zuerich | Metal complexes |
| JP5829919B2 (ja) * | 2010-02-05 | 2015-12-09 | ナミックス株式会社 | 金属導電性ペースト用の還元剤組成物 |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3784453A (en) * | 1970-12-16 | 1974-01-08 | H Dworkin | Process and apparatus for making radioactive labeled protein material |
| DE2166643A1 (de) * | 1971-03-25 | 1975-01-30 | Minnesota Mining & Mfg | Verfahren zum radioaktiven kennzeichnen von pharmazeutisch unbedenklichen mikropartikeln |
| DE2127809A1 (en) * | 1971-06-01 | 1972-12-14 | Kort, Waiter, Dr , 1000 Berlin | Radioactive technetium-iron complex - for scintigraphy of organs and blood vessels |
| US3725295A (en) * | 1971-07-20 | 1973-04-03 | Atomic Energy Commission | Technetium labeling |
| US3873680A (en) * | 1972-08-30 | 1975-03-25 | Minnesota Mining & Mfg | Mercaptan and thioketal complexes of technetium 99M for diagnostic scanning |
| US3868383A (en) * | 1973-04-23 | 1975-02-25 | Lilly Co Eli | Process for preparing 5-({60 -cyanobenzylidene) oxazolidine-2, 4-diones |
| CA1070695A (en) * | 1975-09-02 | 1980-01-29 | Michael D. Loberg | Iminodiacetic acid pharmaceutical |
| DE2543351A1 (de) * | 1975-09-29 | 1977-04-07 | Henkel & Cie Gmbh | Praeparate zur herstellung von 99m technetum-radiodiagnostika |
-
1978
- 1978-05-25 US US05/909,385 patent/US4272503A/en not_active Expired - Lifetime
-
1979
- 1979-01-15 CA CA319,663A patent/CA1111765A/en not_active Expired
- 1979-04-13 JP JP4522679A patent/JPS54160305A/ja active Pending
- 1979-05-16 SE SE7904316A patent/SE7904316L/xx not_active Application Discontinuation
- 1979-05-22 DE DE19792920770 patent/DE2920770A1/de not_active Ceased
- 1979-05-23 GB GB7917979A patent/GB2023327B/en not_active Expired
- 1979-05-23 NL NL7904059AA patent/NL7904059A/xx not_active Application Discontinuation
- 1979-05-23 FR FR7913264A patent/FR2430236A1/fr active Granted
- 1979-05-25 CH CH4896/79A patent/CH649924A5/de not_active IP Right Cessation
- 1979-05-25 BE BE0/195405A patent/BE876562A/xx not_active IP Right Cessation
-
1982
- 1982-10-15 JP JP57181234A patent/JPS58146514A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| US4272503A (en) | 1981-06-09 |
| GB2023327B (en) | 1982-08-25 |
| GB2023327A (en) | 1979-12-28 |
| JPS58146514A (ja) | 1983-09-01 |
| SE7904316L (sv) | 1979-11-26 |
| FR2430236A1 (fr) | 1980-02-01 |
| JPS54160305A (en) | 1979-12-19 |
| DE2920770A1 (de) | 1979-11-29 |
| FR2430236B1 (cg-RX-API-DMAC7.html) | 1983-05-13 |
| NL7904059A (nl) | 1979-11-27 |
| CH649924A5 (de) | 1985-06-28 |
| BE876562A (fr) | 1979-11-26 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CA1111765A (en) | Reductant composition for technetium-99m and method for making technetium-99m labelled ligands | |
| AU748213B2 (en) | Method for the preparation of facial metal tricarbonyl compounds and their use in the labelling of biologically active substrates | |
| EP0111415B1 (en) | Process for making lyophilized radiographic imaging kit | |
| US5601800A (en) | New multifunctional ligands for potential use in the design therapeutic or diagnostic radiopharmaceutical imaging agents | |
| JPS58126817A (ja) | 放射性核種標識タンパク質、とくに抗体または抗体断片の製造法 | |
| NL8002235A (nl) | Werkwijze ter bereiding van een 195au bevattende vloeistof, werkwijze voor het uitvoeren van een radiodiagnostisch onderzoek, en radioisotopengenerator geschikt om een 195au bevattende vloeistof te genereren. | |
| EP3452436A2 (en) | In-kit preparation of gallium-68 labelled radiopharmaceuticals | |
| EP1192166B1 (en) | Group(vii) transition-metal complexes with multidentate aminopolycarboxylate ligands and a kit for producing them | |
| CA2031585A1 (en) | 10-(2'-hydroxy-3'-alkoxy-1,4,7-triscarboxymethyl-1,4,7,10-t etraazacyclododecanes | |
| US6926883B1 (en) | Group (VII) transition-metal complexes with multidentate aminopolycarboxylate ligands and a kit for producing them | |
| CA1067403A (en) | Technetium-99m labeled radiodiagnostic agents for liver and bone marrow scanning and method of preparation | |
| JPS59116233A (ja) | 放射線透過写真の映像用試薬およびその製法 | |
| Thornback et al. | Technetium-99m-Ethylenediamine: A new cationic complex of technetium | |
| JPH01186899A (ja) | 膜透過性を有するＴｃ−９９ｍ単核錯体 | |
| Molinski et al. | Technetium-99m labeled radiodiagnostic agents and method of preparation | |
| JPH0759524B2 (ja) | 放射性医薬品とその調製用高分子化合物 | |
| CA2138522A1 (en) | Hexadentate ligands useful in radiographic imaging agents | |
| Vos | Labeled bleomycin as a tumor localizing agent | |
| JPH08253581A (ja) | 生理活性物質結合高分子化合物および当該化合物を含む放射性医薬品調製用キャリアー | |
| EP0163701A1 (en) | PREPARATION OF RADIOPHARMACEUTICALS BASED ON TECHNETIUM-99m/ | |
| JPS58162533A (ja) | テクネチウム−９９「めゞとる」で放射線標識した物質の精製方法及び装置 | |
| IL150001A (en) | Method for the preparation of facial metal tricarbonyl compounds and their use in the labelling of biologically active substrates |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| MKEX | Expiry |